Atara Biotherapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Atara Biotherapeutics (ATRA).

Price Target Range — 10 Quarters

Analyst Consensus — 8 Analysts

3Buy

4Hold

1Sell

Consensus RatingBuy# Analysts8Avg. Consensus PT$22Upside to Avg. PT+165.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 18, 2026	Freedom Broker	Ilya Zubkov	Upgrade	Sell→Hold	$4→$10
May 8, 2026	Canaccord Genuity	John Newman	Upgrade	Hold→Buy	$6→$13
Jan 21, 2026	Freedom Broker	Ilya Zubkov	Downgrade	Buy→Sell	$16→$4
Jan 13, 2026	Canaccord Genuity	John Newman	Downgrade	Buy→Hold	$25→$6
Dec 19, 2025	Canaccord Genuity	John Newman	PT Raise	Buy	$17→$25
Jul 28, 2025	Freedom Broker	Ilya Zubkov	PT Raise	Sell	$13→$16
May 23, 2025	Freedom Broker	Ilya Zubkov	PT Raise	Sell	$11→$13
Mar 13, 2025	Freedom Broker	Ilya Zubkov	PT Cut	Sell	$13→$11
Mar 11, 2025	Canaccord Genuity	John Newman	Maintained	Buy	$17
Jan 28, 2025	HC Wainwright & Co.	Robert Burns	Maintained	Neutral	—
Jan 22, 2025	HC Wainwright & Co.	Robert Burns	Maintained	Neutral	—
Jan 17, 2025	Canaccord Genuity	John Newman	PT Cut	Buy	$21→$17
Dec 20, 2024	Rodman & Renshaw	Tony Butler	Initiate	Buy	$25
Nov 13, 2024	Canaccord Genuity	John Newman	PT Raise	Buy	$13→$21
Aug 21, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Neutral	—
Aug 16, 2024	Mizuho	Salim Syed	Upgrade	Neutral→Outperform	$25→$18
Aug 13, 2024	Canaccord Genuity	John Newman	Maintained	Buy	$13
Jul 17, 2024	Goldman Sachs	Tommie Reerink	PT Cut	Sell	$13→$11
May 22, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Neutral	—
Apr 1, 2024	Stifel	Benjamin Burnett	PT Cut	Hold	$120→$58

Analyst Ratings News

PRO
Canaccord Genuity Upgrades Atara Biotherapeutics to Buy, Raises Price Target to $13

Canaccord Genuity analyst John Newman upgrades Atara Biotherapeutics (NASDAQ:ATRA) from Hold to Buy and raises the price target from $6 to $13.

Benzinga Newsdesk

PRO
Canaccord Genuity Downgrades Atara Biotherapeutics to Hold, Lowers Price Target to $6

Canaccord Genuity analyst John Newman downgrades Atara Biotherapeutics (NASDAQ:ATRA) from Buy to Hold and lowers the price target from $25 to $6.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Raises Price Target to $25

Canaccord Genuity analyst John Newman maintains Atara Biotherapeutics (NASDAQ:ATRA) with a Buy and raises the price target from $17 to $25.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Maintains $17 Price Target

Canaccord Genuity analyst John Newman maintains Atara Biotherapeutics (NASDAQ:ATRA) with a Buy and maintains $17 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral

HC Wainwright & Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:ATRA) from Neutral to Neutral.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral

HC Wainwright & Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:ATRA) from Neutral to Neutral.

Benzinga Newsdesk

Atara Biotherapeutics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Atara Biotherapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Canaccord Genuity Upgrades Atara Biotherapeutics to Buy, Raises Price Target to $13

PRO
Canaccord Genuity Downgrades Atara Biotherapeutics to Hold, Lowers Price Target to $6

PRO
Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Raises Price Target to $25

PRO
Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Maintains $17 Price Target

PRO
HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral

PRO
HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral

People Also Watch

People Also Watch

Atara Biotherapeutics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Atara Biotherapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCanaccord Genuity Upgrades Atara Biotherapeutics to Buy, Raises Price Target to $13

PROCanaccord Genuity Downgrades Atara Biotherapeutics to Hold, Lowers Price Target to $6

PROCanaccord Genuity Maintains Buy on Atara Biotherapeutics, Raises Price Target to $25

PROCanaccord Genuity Maintains Buy on Atara Biotherapeutics, Maintains $17 Price Target

PROHC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral

PROHC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral

People Also Watch

People Also Watch

PRO
Canaccord Genuity Upgrades Atara Biotherapeutics to Buy, Raises Price Target to $13

PRO
Canaccord Genuity Downgrades Atara Biotherapeutics to Hold, Lowers Price Target to $6

PRO
Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Raises Price Target to $25

PRO
Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Maintains $17 Price Target

PRO
HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral

PRO
HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral